Biotech Movers

Updated August 29, 2026

Stocks with the most signal activity right now: fund position changes, insider purchases, and upcoming catalysts from 20 specialist biotech hedge funds. Ranked by composite activity score.

How the activity score works

What counts as a mover?

Any biotech stock with recent signal activity: new or changed fund positions from the latest 13F filings, insider purchases in the last 30 days, or an upcoming catalyst within 90 days. Stocks are ranked by an activity score that weights these signals.

How often is this updated?

This page refreshes every hour. Fund position data updates quarterly after 13F filing deadlines. Insider signals are ingested daily from SEC EDGAR Form 4 filings. Catalyst dates are refreshed weekly.

What does the activity score mean?

The activity score combines the number of funds with recent position changes, insider buying activity and dollar volume, catalyst proximity, and fund convergence. Higher scores indicate more concurrent signal activity around a stock.

Are exits and trims included?

Yes. Fund exits and trims appear in the table because they are actionable signals. A multi-fund exit from a stock is just as informative as a multi-fund accumulation.

439 active tickers0 with insider buys27 catalysts in 30d

Ticker	Fund Signal	Funds↕	Insider Buys↕	Next Catalyst↕	Score?↓
TNGX Tango Therapeutics Inc.	Trimmed Cormorant Asset Management, Perceptive Advisors +8	4	—	214d Ph2	170
CNTA Centessa Pharmaceuticals plc	Exited Deep Track Capital, BVF Partners +8	2	—	124d Ph2	155
RNA Avidity Biosciences Inc.	Exited Avoro Capital Advisors, Commodore Capital +5	4	—	2d Ph3	150
GPCR Structure Therapeutics Inc.	Trimmed Cormorant Asset Management, RA Capital Management +4	6	—	2d Ph2	135
IMVT Immunovant Inc.	Held Baker Bros. Advisors, Commodore Capital +5	3	—	63d Ph2	125
IDYA IDEAYA Biosciences Inc.	Added Baker Bros. Advisors, RTW Investments +4	4	—	139d Ph3	120
RLAY Relay Therapeutics Inc.	Exited Eventide Asset Management, Tang Capital Management +5	3	—	—	120
CYTK Cytokinetics Incorporated	Added Avoro Capital Advisors, Baker Bros. Advisors +4	3	—	—	115
NBIX Neurocrine Biosciences Inc.	Exited Deep Track Capital, Eventide Asset Management +5	1	—	170d Ph2	110
CGON CG Oncology, Inc.	Exited Avoro Capital Advisors, Perceptive Advisors +4	3	—	214d Ph2	110
SRPT Sarepta Therapeutics Inc.	Exited Perceptive Advisors, EcoR1 Capital +5	2	—	63d Ph3	110
DSGN Design Therapeutics, Inc.	Exited Rock Springs Capital, Cormorant Asset Management +3	3	—	20d Ph3	110
AGIO Agios Pharmaceuticals Inc.	Exited Deep Track Capital, Tang Capital Management +4	4	—	—	105
MRSN Mersana Therapeutics Inc.	Exited Redmile Group, OrbiMed Advisors +5	1	—	—	105
CLDX Celldex Therapeutics Inc.	Added Rock Springs Capital, EcoR1 Capital +4	1	—	63d Ph3	105
ALKS Alkermes plc	Exited Avoro Capital Advisors, Commodore Capital +4	1	—	32d Ph3	100
PCVX Vaxcyte Inc.	Exited Avoro Capital Advisors, Baker Bros. Advisors +3	3	—	155d Ph3	95
AAVXF Abivax S.A.	Exited Commodore Capital, Perceptive Advisors +4	2	—	124d Ph2	95
BEAM Beam Therapeutics Inc.	Exited Rock Springs Capital, Deep Track Capital +3	3	—	124d Ph2	95
VRNA Verona Pharma plc	Exited Cormorant Asset Management, RTW Investments +4	2	—	124d Ph2	95
VSTM Verastem, Inc.	Exited Deerfield Management, Baker Bros. Advisors +2	2	—	2d Ph2	90
CMPS COMPASS Pathways plc	Trimmed OrbiMed Advisors, EcoR1 Capital +4	2	—	—	90
RYTM Rhythm Pharmaceuticals Inc.	Added Rock Springs Capital, Driehaus Capital +2	4	—	63d Ph2	90
TERN Terns Pharmaceuticals Inc.	Exited Deerfield Management, Cormorant Asset Management +4	2	—	—	90
BCRX BIOCRYST PHARMACEUTICALS INC	Exited Driehaus Capital, Baker Bros. Advisors +3	3	—	—	90
TYRA Tyra Biosciences, Inc.	Added OrbiMed Advisors, Deerfield Management +2	3	—	93d Ph2	90
XENE Xenon Pharmaceuticals Inc.	Exited BVF Partners, Commodore Capital +2	2	—	2d Ph3	90
MIRM Mirum Pharmaceuticals Inc.	Added Perceptive Advisors, BVF Partners	3	—	2d Ph3	85
NRIX Nurix Therapeutics Inc.	Added Perceptive Advisors, EcoR1 Capital +3	1	—	—	85
KOD Kodiak Sciences Inc.	Added Driehaus Capital, EcoR1 Capital +1	1	—	2d Ph3	85
IRON Disc Medicine Inc.	Exited Cormorant Asset Management, OrbiMed Advisors +2	4	—	32d Ph3	85
NUVL Nuvalent Inc.	Exited Driehaus Capital, Baker Bros. Advisors +2	3	—	489d Ph2	80
NKTX Nkarta, Inc.	Exited Baker Bros. Advisors, EcoR1 Capital +3	1	—	244d Ph2	80
VRTX Vertex Pharmaceuticals Inc.	Exited OrbiMed Advisors, Driehaus Capital +2	—	—	19d Ph3	80
ACAD ACADIA Pharmaceuticals Inc.	Exited Perceptive Advisors, Eventide Asset Management +3	2	—	124d Ph2	80
FOLD Amicus Therapeutics Inc.	Exited Rock Springs Capital, Perceptive Advisors +2	3	—	124d Ph3	80
ASND Ascendis Pharma A/S	Exited Tang Capital Management, OrbiMed Advisors +2	3	—	305d Ph3	80
BPMC Blueprint Medicines Corporation	Exited Casdin Capital, Rock Springs Capital +3	2	—	124d Ph2	80
EXAS Exact Sciences Corporation	Exited Perceptive Advisors, OrbiMed Advisors +2	3	—	108d Ph2	80
RVMD Revolution Medicines Inc.	Trimmed Rock Springs Capital, Driehaus Capital +2	3	—	259d Ph2	80
KYMR Kymera Therapeutics Inc.	Trimmed Driehaus Capital, EcoR1 Capital +2	3	—	305d Ph2	80
MDGL Madrigal Pharmaceuticals Inc.	Trimmed Driehaus Capital, Baker Bros. Advisors +3	2	—	124d Ph3	80
SYRE Spyre Therapeutics, Inc.	Exited EcoR1 Capital, Driehaus Capital +3	2	—	63d Ph2	80
FDMT 4D Molecular Therapeutics, Inc.	Exited Redmile Group, Deep Track Capital +2	3	—	214d Ph2	80
IVVD Invivyd, Inc.	Exited Deep Track Capital, Tang Capital Management +1	—	—	2d Ph3	75
PTGX Protagonist Therapeutics Inc.	Exited Deep Track Capital, BVF Partners +3	2	—	—	75
GH Guardant Health Inc.	Exited Deerfield Management, Rock Springs Capital +3	2	—	—	75
UNH UNITEDHEALTH GROUP INC	Exited Deerfield Management, Perceptive Advisors +3	1	—	—	75
ENGNW enGene Holdings Inc.	Trimmed Perceptive Advisors, Cormorant Asset Management +3	1	—	—	75
INCY Incyte Corporation	Held Baker Bros. Advisors, Deerfield Management +1	2	—	3d Ph3	75

Showing 50 of 439

Get movers before the market opens

Fund moves, insider buys, and catalyst alerts — delivered free every Monday.

See why TNGX is active — and what comes next

AI context on every fund move, insider trade, and catalyst. Full access for 14 days. Card required, no charge until day 15. Cancel anytime.

Start 14-Day Free Trial

Drill into any signal

Fund Convergence

See which stocks multiple specialist funds are buying at once

Catalyst Calendar

Every PDUFA date, Phase 3 readout, and AdCom in one view

Insider Trading

When executives buy their own stock — the strongest bullish signal

Cash Runway

Which biotechs are running low on cash and face dilution risk

Short Squeeze

High short interest + fund buying + upcoming catalyst = squeeze setup

Signal Rankings

Every signal in one composite score — ranked by conviction

13F Changes

What top biotech funds bought and sold in the latest 13F filing

Want AI context on every signal? Start free trial →